AE	Adverse Events
ALK	Anaplastic Lymphoma Kinase
BC	Bladder Cancer
BCG	Bacillus Calmette–Guérin
BCRP	Bruton’s Tyrosine-Kinase
COX-2	Cyclooxygenase-2
CRS	Central Serous Retinophaty
CT	Chemotherapy
DFS	Disease-Free Survival
DLL	Delta-like canonical NOTCH ligand
DLT	Dose-limiting toxicity
EGF	Epidermal Growth Factor
EGFR	Epidermal Growth Factor Receptor
FDA	Food and Drug Administration
FGF	Fibroblast Growth Factor
FGFR	Fibroblast Growth Factor Receptor
FISH	Fluorescence In Situ Hybridization
HDI	Human Development Index
HGF	Hepatocyte Growth Factor
HIP	Hypoxia Inducible Factor
HR	Hazard Ratio
IHC	Immunohistochemistry
iNOS	Inducible Nitric Oxide Synthase
IT	Immunotherapy
ICI	Immune Checkpoint Inhibitors
JAG	Jagged Canonical NOTCH ligand
MAPK	Mitogen Activated Protein-Kinase
MIBC	Muscle-Invasive Bladder Cancer
miRNAs	micro-RNAs
mOS	Median Overall Survival
mPFS	Median Progression–Free Survival
mTOR	Mamalian Target of Rapamycin
mUC	Metastatic Urothelial Cancer
NGS	Next-Generation Sequencing
NMIBC	Non-Muscle-Invasive Bladder Cancer
ORR	Overall Response Rate
OS	Overall Survival
PCNA	Proliferating Cell Nuclear Antigen
PDGF	Platelet-Derived Growth Factor
PFS	Progression-Free Survival
PI3K	Phosphatidylinositol-3-kinase
PKC	Protein kinase C
PLC	Phosphatidylinositol-Specific Phospholipase C
PUMA	p53-Upregulated Modulator of Apoptosis
RFS	Recurrence-free survival
RON	Recepteur d’Origine Nantais
SCC	Squamous Cell Carcinoma
TCGA	The Cancer Genome Atlas
TSC	Tuberous Sclerosis Complex
TGF	Transforming Growth Factor
TMB	Tumor Mutation Burden
UUT-TCC	Upper urinary tract transitional cell carcinoma
VEGF	Vascular Endothelial Growth Factor
VEGFR	Vascular Endothelial Growth Factor Receptor